Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Interest Income

Income earned on cash, deposits, and investments held by the company.

Adagene Inc.NASDAQ: ADAG

Interest Income · Q4 FY2025 · quarter ended Dec 2025

Interest income dips below year-ago levels

Q4 FY2025 interest income of $1.09M fell 40.1% year over year, behind the +101.9% change in trailing-twelve-month interest income. Over 3 fiscal years it compounded at +82.7% a year.

Context

  • Interest income amounted to 30.0% of revenue in FY2025, down 3653.3 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -40.1% toward the trailing-twelve-month pace of +101.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.09M— QoQ
Last fiscal yearDec 2025
$2.3M-39.4% YoY
LTMJun 2024
$6.08M+101.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.1%——
1 year-39.4%——
3-year CAGR+82.7%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.3M USD
Year-over-year change
-39.4%
4-year CAGR
+134.5%

Interest Income vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 interest income of $6.08M is the 2nd highest of the 9 companies compared; the peer median is $1.43M.
  • Interest income amounts to 745.4% of revenue for ADAG, versus a peer median of 2.6%.
ADAG Competitors Peer median
Interest Income for ADAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$7.18M -43.4%+77.0%78.5%
ADAGAdagene Inc.LTM Jun 2024$6.08M —+82.7%745.4%
ACETAdicet Bio, Inc.LTM Mar 2026$5.44M -42.7%+15.4%—
XBITXBiotech Inc.LTM Mar 2026$5.09M -41.2%+14.1%—
FBIOFortress Biotech, Inc.LTM Mar 2026$2.57M +9.7%+21.1%3.9%
GANXGain Therapeutics, Inc.LTM Mar 2026$297.03K +5.3%-13.3%—
NTRBNutriband Inc.LTM Apr 2026$22.17K -90.0%—1.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$13K -38.1%-63.6%0.6%
OSTXOS Therapies IncorporatedLTM Mar 2026$228 +245.5%——
Peer median (excluding ADAG) $1.43M-39.7%+14.7%2.6%

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.18M9.29M18.11M103.2K7.67M
Cost of Revenue00000
Gross Profit10.18M9.29M18.11M(823.04K)7.67M
Gross Margin100.0%100.0%100.0%-797.5%100.0%
Research & Development68.1M81.34M36.64M28.78M22.03M
Selling, General & Admin14.44M11.87M8.67M7.27M7.08M
Operating Expenses82.54M93.21M41.83M36.05M29.11M
Depreciation & Amortization1.13M1.43M1.21M926.25K589.79K
EBITDA(69.99M)(77.39M)(14.95M)(31.66M)(16.85M)
EBITDA Margin-687.8%-832.8%-82.5%-30680.5%-219.7%
Operating Income(72.36M)(83.92M)(23.72M)(35.95M)(21.44M)
Operating Margin-711.2%-903.1%-131.0%-34835.4%-279.5%
Interest Income76.17K377.5K4.28M3.8M2.3M
Interest Expense363.76K693.32K1.11M851.87K463.13K
Other Income / Expenses887.77K4.41M6.46M2.51M3.53M
Income Before Tax(71.48M)(79.51M)(17.25M)(33.44M)(17.91M)
Pre-Tax Margin-702.5%-855.6%-95.3%-32403.5%-233.4%
Income Tax Expense1.7M459.06K1.69M(17.55K)(297.86K)
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Net Margin-719.2%-860.6%-104.6%-32386.4%-229.6%
EPS (Basic)(2.29)(2.31)(0.55)(0.95)(0.46)
EPS (Diluted)(2.29)(2.31)(0.54)(0.95)(0.46)
Weighted Avg Shares32.02M34.65M34.64M36.02M37.76M
Weighted Avg Shares (Diluted)32.02M34.65M35.03M36.02M37.76M

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.